| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 65.222 | 93.746 | 110.324 | 106.728 | 170.527 | 225.121 | 438.568 | 603.582 | 840.880 | 1.082.777 |
| Total Income - EUR | 78.007 | 101.669 | 117.325 | 143.859 | 216.116 | 275.085 | 647.219 | 744.231 | 1.145.420 | 1.484.446 |
| Total Expenses - EUR | 64.435 | 91.126 | 103.982 | 144.752 | 207.792 | 265.709 | 615.996 | 701.152 | 1.042.775 | 1.347.817 |
| Gross Profit/Loss - EUR | 13.572 | 10.542 | 13.343 | -894 | 8.324 | 9.376 | 31.224 | 43.080 | 102.645 | 136.629 |
| Net Profit/Loss - EUR | 11.580 | 9.605 | 12.093 | -1.963 | 6.614 | 7.488 | 27.318 | 37.823 | 91.287 | 117.520 |
| Employees | 3 | 3 | 4 | 3 | 4 | 5 | 6 | 7 | 7 | 7 |
Check the financial reports for the company - Doremavix Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 56.171 | 51.369 | 46.530 | 63.734 | 170.095 | 152.317 | 135.352 | 123.814 | 119.470 | 308.123 |
| Current Assets | 89.845 | 121.482 | 124.593 | 114.662 | 176.559 | 191.776 | 383.249 | 406.669 | 493.955 | 627.879 |
| Inventories | 58.550 | 82.774 | 72.605 | 89.000 | 117.666 | 109.907 | 316.991 | 335.084 | 360.467 | 478.253 |
| Receivables | 27.528 | 29.592 | 35.052 | 11.480 | 44.540 | 39.700 | 28.616 | 49.531 | 63.776 | 79.417 |
| Cash | 3.767 | 9.116 | 16.936 | 14.183 | 14.353 | 42.169 | 37.642 | 22.054 | 69.712 | 70.209 |
| Shareholders Funds | 11.713 | 21.198 | 32.933 | 30.365 | 36.391 | 43.189 | 69.549 | 87.310 | 148.007 | 264.699 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 134.303 | 151.653 | 138.191 | 148.031 | 310.262 | 300.904 | 449.052 | 443.173 | 465.418 | 671.303 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4777 - 4777" | |||||||||
| CAEN Financial Year |
4777
|
|||||||||
Comments - Doremavix Srl